Dr Rositsa Koleva-Kolarova
Rositsa joined HERC in May 2019 as a senior researcher. Currently she works on a Horizon2020 funded project called HEcoPerMed (Health Economics for Personalised Medicine), which aims to provide guidance on state-of-the-art health economic modelling, and on financing and payment strategies for personalised medicine, to distinguish promises from reality.
Previously she held an appointment as a research fellow in health economics in the Department of Population Health Sciences, School of Population Health & Environmental Sciences, King’s College London. She worked on economic evaluation projects on stratifying antihypertensive treatment according to individuals’ ethnicity background, pharmacogenetics and pharmacogenomics for cardiovascular diseases, and evaluating new models of care (Vanguards).
Rositsa obtained her PhD from the University of Groningen, the Netherlands, and held an appointment as an assistant professor at the Department of Public Health Sciences, Faculty of Public Health, Medical University Pleven, Bulgaria.
Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations
Lim KK. et al, (2021), The Pharmacogenomics Journal
IT Evaluation of Foundation Healthcare Group Vanguard Project.
Tapuria A. et al, (2021), Stud Health Technol Inform, 281, 625 - 629
Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine.
Vellekoop H. et al, (2021), Pharmacoeconomics
FINANCING AND REIMBURSEMENT FOR PERSONALISED MEDICINE - ARE WE THERE YET?
Koleva-Kolarova R. et al, (2020), VALUE IN HEALTH, 23, S756 - S756
Large expert-curated database for benchmarking document similarity detection in biomedical literature search
Brown P. et al, (2019), DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION